Table 1.
The baseline characteristics of all selected patients with hepatocellular carcinoma (HCC)
| Characteristic | Total ( n = 224) | Antiviral treatment group ( n = 80) | Non-antiviral treatment group ( n = 144) | P value c | |
|---|---|---|---|---|---|
| Sex (males:females) | 209:15 | 78:2 | 131:13 | 0.092 | |
| Age (years) a | 49.5 (38.5, 58.0) | 48.0 (39.5, 56.0) | 50.5 (38.0, 59.0) | 0.574 | |
| WBC (×10 9 /L) | 6.66 ± 2.12 | 6.38 ± 1.85 | 6.82 ± 2.25 | 0.286 | |
| HBG (g/L) | 137.91 ± 20.28 | 137.90 ± 22.36 | 137.90 ± 19.10 | 0.987 | |
| PLT (×10 9 /L) | 179.91 ± 84.16 | 170.30 ± 88.10 | 185.24 ± 81.71 | 0.076 | |
| ALT (U/L) | 58.38 ± 40.62 | 65.28 ± 44.99 | 54.54 ± 37.60 | 0.081 | |
| AST (U/L) | 84.89 ± 62.44 | 91.17 ± 63.80 | 81.40 ± 61.62 | 0.125 | |
| ALB (g/L) | 40.10 ± 4.40 | 39.30 ± 4.55 | 40.54 ± 4.26 | 0.032 | |
| TBIL (μmol/L) | 16.44 ± 7.61 | 17.73 ± 8.49 | 15.72 ± 6.99 | 0.059 | |
| AFP (ng/mL) a | 1301 (50, 38,398) | 1436 (53, 37,546) | 1210 (50.74, 39,410) | 0.820 | |
| AFP (<1,000 ng/mL:>1,000 ng/mL) | 108:116 | 39:41 | 69:75 | 0.905 | |
| PT (s) | 12.58 ± 2.08 | 12.83 ± 2.05 | 12.44 ± 2.09 | 0.052 | |
| APPT (s) | 27.95 ± 3.85 | 28.22 ± 3.69 | 27.80 ± 3.94 | 0.278 | |
| HBeAg (positive:negative) | 53:171 | 24:56 | 29:115 | 0.096 | |
| HBV DNA (log 10 IU/mL) | 4.85 ± 1.86 | 5.50 ± 1.58 | 4.48 ± 1.92 | <0.001 | |
| UICC TNM stage (I:II:IIIa:IIIb + IIIc:IV) | 46:25:68:63:22 | 9:14:25:26:6 | 37:11:43:37:16 | 0.024 | |
| TNM stage (early:advanced) | 71:153 | 23:57 | 48:96 | 0.480 | |
| Cycles of TACE (one:more than one) | 133:91 | 37:43 | 96:48 | 0.003 | |
| Resection after TACE (yes:no) | 19:205 | 7:73 | 12:132 | 0.915 | |
| Local ablation after TACE (yes:no) | 49:175 | 23:57 | 26:118 | 0.064 | |
| Sorafenib therapy after TACE (yes: no) | 12:212 | 6:74 | 6:138 | 0.288 | |
| Subsequent therapy b after TACE (yes:no) | 67:157 | 30:50 | 37:107 | 0.065 | |
|
Chemotherapeutic agents
(epirubicin only:>2 agents) |
53:171 | 18:62 | 35:109 | 0.761 |
aThe values are presented as median followed by interquartile (P25 and P75) in the parentheses. bSubsequent therapy means any treatment after TACE, including resection, local ablation, or sorafenib therapy. cDifferences between the antivirus group and the non-antivirus group. WBC, white blood cells; HBG, hemoglobin; PLT, platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; TBIL, total bilirubin; AFP, α-fetoprotein; PT, prothrombin time; APTT, activated partial thromboplastin time; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; UICC TNM, International Union Against Cancer tumor-node-metastasis; TACE, transcatheter arterial chemoembolization.